subgroups – Page 6 – Communicable Diseases Research

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

입원하지 않은 환자의 코로나19 경구 치료용 몰누피라비르

Clinical Trial

Published on 2022-02-102022-09-11
Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, 치료제,

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

Randomized Controlled Trial

Published on 2022-02-102022-10-04
Journal: The European Respiratory Journal [Category] COVID19(2023년), SARS, 임상,

[키워드] 1:1 28-day mortality 95% CI age Antibody titre assigned baseline Clinical improvement clinical trial convalescent plasma coronavirus disease COVID-19 Critically ill days alive Effect enrolment group groups hospitalised hospitalised patient interquartile range invasive investigator-initiated IQR Laboratory male marker median no significant difference Open-label Parallel Arm Patient patients plasma Primary outcome proportion randomisation randomised Randomly Respiratory Support Secondary outcomes Standard of care subgroups symptom onset the median therapy Trial ventilatory support with COVID-19
[DOI] 10.1183/13993003.01471-2021 PMC 바로가기 [Article Type] Randomized Controlled Trial

Characteristics, Outcomes, and Severity Risk Factors Associated With SARS-CoV-2 Infection Among Children in the US National COVID Cohort Collaborative

미국 국립 COVID 코호트 공동 연구에서 어린이의 SARS-CoV-2 감염과 관련된 특성, 결과 및 심각도 위험 요소

Multicenter Study

Published on 2022-02-082022-09-10
Journal: JAMA Network Open [Category] COVID19(2023년), MERS, SARS, 변종,

[키워드] 95% CI acute COVID-19 Admission assist available data change Characteristics children children with MIS-C chronic condition Clinical data clinical outcomes clinical phenotype cohort study Comorbidity complex conducted COVID criteria death Delta demographic characteristics disease disease severity element ERAS extracorporeal membrane oxygenation Factor finding granular Hospitalization Hospitalized Illness severity Importance incidence Inflammatory initial invasive ventilation knowledge Laboratory Laboratory test lack Male sex measure mechanical ventilation median age MIS-C multicenter obesity objective Odds ratio outcome outcomes participant pediatric Point positive Predictive preexisting comorbidities prospective cohort study Relevance Result risk risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 testing SARS-CoV-2–positive setting severe disease severity Sex subgroups Support syndrome test results tested Trajectories translate understanding utility variable variant vital sign vital signs
[DOI] 10.1001/jamanetworkopen.2021.43151 PMC 바로가기 [Article Type] Multicenter Study

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

입원한 COVID-19 환자를 위한 과면역 면역글로불린(ITAC): 이중 맹검, 위약 대조, 3상, 무작위 시험

Clinical Trial

Published on 2022-02-052022-09-11
Journal: Lancet (London, England) [Category] Fulltext, MERS, 임상, 진단, 치료제,

[키워드] 1:1 95% CI addition adjusted Administered adverse events Analysis Anti-spike antibody assigned baseline carried clinical care clinical trials Complication COVID-19 death donors double-blind duration of symptoms Efficacy Efficacy and safety eligibility criteria end-organ Endpoint enrolled Evidence evidence of Factors finding greater Group allocation heterogeneity hospitalised hospitalised patient Hospitalised patients hyperimmune Immunoglobulin Immunotherapy Infection infusion Interaction International Intravenous immunoglobulin investigators mass mITT mITT analysis modified intention-to-treat Neutralising Antibodies neutralising antibody Organ failure outbreak outcome participant Passive Patient Phase 3 Placebo placebo group placebo-controlled placebo-controlled trial positive Primary outcome randomisation randomised randomised clinical trial Randomised trial Randomly ranged reaction receive Registered Remdesivir Research risk Saline SARS-CoV-2 serious infections significantly Standard of care stratified subgroup subgroups Symptom symptomatic therapy to define Treatment treatment of COVID-19 Trial trial participant trial participants Volume was measured were used with COVID-19
[DOI] 10.1016/S0140-6736(22)00101-5 PMC 바로가기 [Article Type] Clinical Trial

How Did the COVID-19 Pandemic Affect Migrant Populations in Lisbon, Portugal? A Study on Perceived Effects on Health and Economic Condition

Article

Published on 2022-02-042022-10-29
Journal: International Journal of Environmental Research an [Category] Coronavirus, COVID19(2023년), MERS, SARS,

Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study

항암제 치료 클래스는 암 환자에서 COVID-19 mRNA-BNT162b2 백신 면역원성을 조절합니다: 전향적 Vax-On 연구의 2차 분석

Article

Published on 2022-02-012022-09-12
Journal: ESMO open [Category] COVID19(2023년), MERS, SARS, 진단, 치료법,

[키워드] accounted Analysis antibody Antibody Response Antineoplastic Cancer cancer treatment carried Chemotherapy classification Cooperative correlated correlation Corticosteroid COVID-19 COVID-19 vaccination COVID-19 vaccine Cytotoxic chemotherapy defined DNA dose drug Effect enrolled granulocyte group humoral IgG Immunoglobulin immunosuppressive inhibitor inhibitors Interaction intravesical lack modulate mTOR inhibitor Patient performance status predicted Rapamycin Receptor binding domain reduced retained second dose Seroconversion seroconversion response significantly significantly lower Specific Spike protein subgroup subgroup analysis subgroups targeted therapy the S1 subunit the SARS-CoV-2 therapy TKI TKIs treated Treatment tyrosine kinase inhibitor Vaccine vaccine immunogenicity Variation
[DOI] 10.1016/j.esmoop.2021.100350 PMC 바로가기 [Article Type] Article

Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials

COVID-19, SARS, MER 또는 인플루엔자로 입원 한 환자의 글루코 코르티코이드, 심혈관 합병증 및 사망률의 전신 투여 : 무작위 시험의 체계적인 검토 및 메타 분석

Meta-Analysis

Published on 2022-02-012022-09-10
Journal: Pharmacological research [Category] COVID19(2023년), MERS, SARS, 임상,

[키워드] 95% CI administration all-cause mortality benefit cardiometabolic cardiovascular complication cardiovascular complications Confidence intervals COVID-19 Dexamethasone Effects estimate Follow-up glucocorticoid Glucocorticoids hospitalised in-hospital mortality Influenza lower mortality Mantel-Haenszel mechanical ventilation MERS Meta-analysis Mortality objective outcomes oxygen Patient patients Placebo random effect randomisation Randomised trial randomised trials receiving reduce reduce mortality reduced reduction renal function reported respiratory Respiratory Support respiratory viral infections Result risk severe COVID-19 significantly standard care Steroids subgroup subgroups systematic review systemic systemic glucocorticoid systemic glucocorticoids Treatment trials Viral was reduced were used with COVID-19 worsening
[DOI] 10.1016/j.phrs.2021.106053 PMC 바로가기 [Article Type] Meta-Analysis

Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients

만성 림프구성 백혈병 환자의 코로나19: 연속 환자에서 13개월 동안 임상 결과 및 B 세포 및 T 세포 면역

Article

Published on 2022-02-012022-09-11
Journal: Leukemia [Category] COVID19(2023년), MERS, SARS, 유전자 메커니즘, 진단, 치료기술,

Mental health outcomes after SARS-CoV-2 vaccination in the United States: A national cross-sectional study

Article

Published on 2022-02-012022-10-30
Journal: Journal of affective disorders [Category] COVID-19, COVID19(2023년), MERS, SARS,

Coronary Stent Thrombosis in COVID-19 Patients: A Systematic Review of Cases Reported Worldwide

Review

Published on 2022-01-272022-10-28
Journal: Viruses [Category] COVID-19,